Journal
FRONTIERS IN IMMUNOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.628453
Keywords
butyrate; SCFA (short chain fatty acids); allergic asthma; epigenetics; microbiome; inflammation; cell fate and differentiation; HDAC inhibitor (histone deacetylase inhibitor)
Categories
Funding
- Canadian Institutes of Health Research Operating Grant: Impact Grant: CEEHRC Phase II [IGH-155177, PJT-438586]
- Centre for Blood Research Graduate Awards Program at the University of British Columbia
Ask authors/readers for more resources
The gut-lung axis highlights the crucial biological crosstalk between the intestinal microbiome and lung, which may be a driving force behind the development of allergic asthma.
The microbiome plays a fundamental role in how the immune system develops and how inflammatory responses are shaped and regulated. The gut-lung axis is a relatively new term that highlights a crucial biological crosstalk between the intestinal microbiome and lung. A growing body of literature suggests that dysbiosis, perturbation of the gut microbiome, is a driving force behind the development, and severity of allergic asthma. Animal models have given researchers new insights into how gut microbe-derived components and metabolites, such as short-chain fatty acids (SCFAs), influence the development of asthma. While the full understanding of how SCFAs influence allergic airway disease remains obscure, a recurring theme of epigenetic regulation of gene expression in several immune cell compartments is emerging. This review will address our current understanding of how SCFAs, and specifically butyrate, orchestrates cell behavior, and epigenetic changes and will provide a detailed overview of the effects of these modifications on immune cells in the context of allergic airway disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available